pISSN 2234-3806eISSN 2234-3814
Table. 2.
Summary of the cost and outcome results in the analysis
| Results | Tissue-only strategy T | issue-first strategy | Plasma-first strategy |
|---|---|---|---|
| First-line treatment of advanced NSCLC | |||
| Sensitizing mutation treated (%) | 84.6 | 92.5 | 96.8 |
| Cost (KRW) | |||
| Total | 1,543,367 | 1,564,432 | 1,004,283 |
| Biopsy | 676,066 | 676,066 | 140,960 |
| Complication | 55,067 | 55,067 | 11,481 |
| 131,505 | 144,656 | 158,924 | |
| Second-line treatment of advanced NSCLC | |||
| Overall survival (months) | 25.0 | 24.9 | 25.9 |
| Progression-free survival (months) | 9.1 | 9.1 | 9.6 |
| T790M mutation treated (%) | 83.2 | 82.2 | 91.7 |
| No. of biopsies | 1.1 | 1.0 | 0.3 |
| Cost (KRW) | |||
| Total | 165,815,059 | 164,137,642 | 179,382,572 |
| Biopsy | 743,672 | 676,066 | 230,538 |
| Complication | 60,573 | 55,067 | 18,778 |
| 144,656 | 144,656 | 176,348 | |
Abbreviations: NSCLC, non-small cell lung cancer; KRW, Korean won; EGFR, epidermal growth factor receptor.
Ann Lab Med 2023;43:605~613 https://doi.org/10.3343/alm.2023.43.6.605
© Ann Lab Med